IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v15y2014i1p53-64.html
   My bibliography  Save this article

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison

Author

Listed:
  • Petra Baji
  • Márta Péntek
  • László Czirják
  • Zoltán Szekanecz
  • György Nagy
  • László Gulácsi
  • Valentin Brodszky

Abstract

This is the first indirect meta-analysis in RA that compares the efficacy and safety of biosimilar-infliximab to the other biologicals indicated in RA. We found no significant difference between infliximab-biosimilar and other biological agents in terms of clinical efficacy and safety. Copyright Springer-Verlag Berlin Heidelberg 2014

Suggested Citation

  • Petra Baji & Márta Péntek & László Czirják & Zoltán Szekanecz & György Nagy & László Gulácsi & Valentin Brodszky, 2014. "Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 53-64, May.
    • Handle: RePEc:spr:eujhec:v:15:y:2014:i:1:p:53-64
    DOI: 10.1007/s10198-014-0594-4
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-014-0594-4
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-014-0594-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Kalle J Aaltonen & Liisa M Virkki & Antti Malmivaara & Yrjö T Konttinen & Dan C Nordström & Marja Blom, 2012. "Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis," PLOS ONE, Public Library of Science, vol. 7(1), pages 1-14, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Petra Baji & Márta Péntek & Sándor Szántó & Pál Géher & László Gulácsi & Orsolya Balogh & Valentin Brodszky, 2014. "Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 45-52, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Saara Huoponen & Kalle J Aaltonen & Jaana Viikinkoski & Jarno Rutanen & Heikki Relas & Kirsi Taimen & Kari Puolakka & Dan Nordström & Marja Blom, 2019. "Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-14, July.
    2. Jaana T Joensuu & Saara Huoponen & Kalle J Aaltonen & Yrjö T Konttinen & Dan Nordström & Marja Blom, 2015. "The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-27, March.

    More about this item

    Keywords

    Arthritis; Rheumatoid; Biosimilar pharmaceuticals; Meta-analysis; Mixed treatment comparison; I10; I19;
    All these keywords.

    JEL classification:

    • I10 - Health, Education, and Welfare - - Health - - - General
    • I19 - Health, Education, and Welfare - - Health - - - Other

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:15:y:2014:i:1:p:53-64. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.